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Results: The median interval between HL and HF was 20.6 
years. Fifty-seven percent of the cases had died at the end of 
follow-up, with a median time from HF to death of 3.6 years 
(interquartile range: 0.2-5.6 years). Mediastinal radiotherapy 
was applied through parallel-opposed fields. Average MHD for 
cases treated with RT was 25 Gy and for controls 22 Gy. Risk 
of HF increased in a non-linear way, with no increase at a 
MHD of 10 Gy, a 1.2-fold increased risk at a MHD of 20 Gy, 
and a 2.5-fold increased risk at a MHD of 30 Gy. Relatively 
low doses of anthracyclines (10-279 mg/m2) were associated 
with a 3.2-fold increased risk of developing HF (95%CI: 1.3-
7.7) compared with patients who did not receive 
anthracyclines. High doses of anthracyclines (280-800 
mg/m2) were associated with a similarly increased risk (RR: 
2.8, 95%CI: 1.6-5.1). For patients who received 
anthracyclines in combination with mediastinal radiotherapy 
the risk of HF (RR: 2.90 at a MHD of 25 Gy) was slightly higher 
than the risk of mediastinal radiotherapy without 
anthracyclines (RR: 1.8 at a MHD of 25 Gy), although the 
difference was not statistically significant (p 
interaction=0.10). Classical risk factors for cardiovascular 
diseases did not confound or modify the association between 
treatment-related risk factors and HF risk. 
 
Conclusion: Risk of HF increased non-linearly with mean 
heart dose in patients treated for HL. Our findings can be 
used to predict HF risk and may therefore be useful for 
patients and doctors both before treatment, during radiation 
treatment planning and in follow-up. Patients who received 
both anthracyclines and mediastinal radiation need to be 
followed carefully. 
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Purpose or Objective: Among 6039 patients with Hodgkin 
lymphoma enrolled in nine successive EORTC-GELA 
randomized trials (1964-2004), the effect of individual 
radiotherapy and chemotherapy doses on the risk of 
developing cardiac disease was investigated. We specifically 
analysed the added value from radiation dose-volume metrics 
on cardiac risk prediction as well as the impact of relapse 
treatment. 
 
Material and Methods: For all patients, dose-volume metrics 
for the heart (mean dose, volume receiving ≥5 Gy (V5Gy), 
V10Gy, V20Gy, V30Gy, V40Gy) were retrospectively 
estimated by reconstructing individual treatments on 
representative computed tomography datasets. Cumulative 
doses of anthracyclines and vinca-alkaloids (mg/m2) were 
also obtained individually. Relapse occurring before a cardiac 
disease was analysed qualitatively (no, yes). Cardiac disease 
was reported during follow-up and through a patient-
reported questionnaire (LSQ responders, 2009-2010 cross-
sectional study). A multivariable Cox proportional hazards 
model with backwards selection was applied to test for 
patient- and treatment-related factors associated with 
cardiac disease. The resulting model was compared to a 
"mean heart dose"-model in terms of prognostic 
discrimination ability. 
 
Results: 599 patients developed at least one cardiac disease 
event (465 events obtained from the 1919 LSQ responders). 
Significant predictors of cardiac disease were: cumulative 
dose of anthracyclines (HR=1.002 per 1 mg/m2 increase in 
cumulative dose; 95% CI, 1.001-1.003, p=0.005); (any) 
treatment given for a relapse (HR=1.286; 95% CI,1.001-1.65, 
p=0.049) and the radiation dose-volume metrics V30Gy 
(HR=1.007 per 1% increase in dose; 95% CI, 1.003-1.011, 
p=0.001) and V40Gy (HR=1.018 per 1% increase in dose; 95% 
CI,1.008-1.029, p<0.001). The freedom from cardiac disease 
estimates with the "V30Gy, V40Gy"-model are plotted against 
a "mean heart dose"-model (= mean heart dose, cumulative 
dose of anthracyclines, any relapse treatment) in figure 1. 
 
 
Figure 1: Freedom from cardiac disease estimates with the 
resulting “V30Gy, V40Gy”-model versus a “mean heart dose”-
model. 
 
Conclusion: In patients treated for Hodgkin lymphoma, the 
radiation dose-volume metrics V30Gy and V40 Gy, the 
cumulative dose of anthracyclines, and (any) treatment given 
for a relapse have a significant impact on the risk of 
subsequent cardiac disease. There seems to be no improved 
discrimination ability of the prognostic model when using 
radiation dose-volume metrics compared to the mean heart 
dose metric. 
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Purpose or Objective: A novel approach to treatment 
planning for focal brachytherapy is described, utilizing a 
biologically-based inverse optimization algorithm and 
